Array BioPharma Inc. (NASDAQ: ARRY) and Global Blood Therapeutics today announced a multi-target drug discovery collaboration agreement to identify small molecule lead compounds targeting chronic blood-based diseases. Array will develop assays and screen its proprietary lead generation library of 300,000 small molecules to identify both active site and allosteric modulators of certain Global Blood targets. Array's library will allow for rapid hit confirmation and subsequent lead optimization.
"We look forward to deploying our drug discovery platform and sharing our expertise with companies like Global Blood, a venture-backed company founded by Third Rock Ventures," said Kevin Koch , Ph.D., President and Chief Scientific Officer for Array. "Our mutual goal is to accelerate the drug discovery and development process by combining Global Blood's expertise in disease biology and computationally supported medicinal chemistry with Array's established drug discovery platform."
"We view this collaboration as a complement to our internal, broad based drug discovery research," said Brian W. Metcalf , Acting Chief Scientific Officer for Global Blood. "This relationship leverages Array's comprehensive drug discovery platform with Global Blood Therapeutics' class-leading expertise in blood biology, with the goal to revolutionize the treatment of chronic blood-based diseases."
Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration